Physician profile
Karyn Teel
NPI 1073771697
$813.80
in general payments reported to CMS, 2019-2025
12 companies · $287 in 2025
The $287 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.17 · 2020: $18.87 · 2021: $23.07 · 2022: $78.02 · 2023: $159 · 2024: $231 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $676.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $322.09 | 2021-2025 | Eylea Hd, Eylea |
| Astellas Pharma US INC | $125.00 | 2024 | Izervay |
| Apellis Pharmaceuticals, INC. | $81.71 | 2023-2025 | Syfovre |
| Abbvie INC. | $77.52 | 2022-2025 | |
| Genentech USA, INC. | $46.59 | 2022-2023 | Vabysmo |
| Dompe US, INC. | $31.47 | 2024 | Oxervate |
| Mallinckrodt Hospital Products INC. | $30.27 | 2025 | Acthar |
| Genentech, INC. | $24.91 | 2023 | Vabysmo |
| Tarsus Pharmaceuticals, INC. | $24.39 | 2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $18.87 | 2020 | |
| Iridex Corporation | $17.17 | 2019 | |
| Oyster Point Pharma, INC. | $13.81 | 2025 | Tyrvaya, Ryzumvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karyn Teel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.